These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2878676)

  • 41. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Lewis RV; McMurray J; McDevitt DG
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):1-6. PubMed ID: 2468920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Xamoterol improves the control of chronic atrial fibrillation in elderly patients.
    Lawson-Matthew PJ; McLean KA; Dent M; Austin CA; Channer KS
    Age Ageing; 1995 Jul; 24(4):321-5. PubMed ID: 7484490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 46. Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris.
    European 'Corwin' Study Group
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):67S-69S. PubMed ID: 2572258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of oral dosing of xamoterol on systolic time intervals in man and xamoterol plasma concentrations in heart failure patients.
    James MA; Papouchado M; Channer KS; Jones JV; Marlow HF; Bastain W; Barker NP; Harry JD; Wardleworth AG
    Br J Clin Pharmacol; 1990 Apr; 29(4):447-53. PubMed ID: 2139340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study.
    Pouleur H; Rousseau MF; Oakley C; Rydén L
    Am J Cardiol; 1991 Jul; 68(1):71-4. PubMed ID: 1676239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Xamoterol versus digoxin in heart failure.
    Lancet; 1988 Apr; 1(8590):877. PubMed ID: 2895376
    [No Abstract]   [Full Text] [Related]  

  • 50. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy-Drager syndrome).
    West JN; Stallard TJ; Dimmitt SB; Smith SA; Williams A; Littler WA
    Q J Med; 1990 Feb; 74(274):209-13. PubMed ID: 1971724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.
    Sorensen EV; Faergeman O; Day M; Bastain W
    Eur J Clin Pharmacol; 1988; 35(2):183-5. PubMed ID: 2903827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term effect of xamoterol "Corwin", beta 1 partial agonist, on hemodynamics and treadmill exercise in patients with previous myocardial infarction].
    Shimizu M; Tsuyusaki T; Kawaguchi T; Kitazumi H; Yoshizawa Y; Kuramochi K; Kawano M; Kodama T; Kawano T; Ogata N
    Kokyu To Junkan; 1988 Dec; 36(12):1339-46. PubMed ID: 2907943
    [No Abstract]   [Full Text] [Related]  

  • 54. Xamoterol in heart failure.
    von Olshausen K
    Lancet; 1988 May; 1(8595):1162. PubMed ID: 2896976
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.
    Pouleur H; Etienne J; Van Mechelen H; Gurné O; Rousseau MF
    Circulation; 1990 Feb; 81(2 Suppl):III87-92. PubMed ID: 1967560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Xamoterol in severe heart failure.
    Ikram H; Crozier IG
    Lancet; 1990 Aug; 336(8713):517-8. PubMed ID: 1975033
    [No Abstract]   [Full Text] [Related]  

  • 57. The efficacy of xamoterol in heart failure of ischemic origin.
    Marlow HF
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S69-72. PubMed ID: 2478814
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of idiopathic orthostatic hypotension with xamoterol.
    Yamashita H; Yahara O; Hasebe N; Kawamura Y; Obara A; Honda H; Kimura T; Onodera S
    Lancet; 1987 Jun; 1(8547):1431-2. PubMed ID: 2884518
    [No Abstract]   [Full Text] [Related]  

  • 59. New evidence on xamoterol.
    Lancet; 1990 Jul; 336(8706):24. PubMed ID: 1973213
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of xamoterol, a beta 1-adrenoceptor partial agonist, on myocardial pH decreased by coronary occlusion in dogs.
    Sashida H; Sakai K; Hino T; Abiko Y
    Pharmacology; 1986; 33(6):301-10. PubMed ID: 2882527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.